Vident Advisory’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Vident Advisory's RPRX Position: Q2 2026 in Review
Vident Advisory increased its Royalty Pharma (RPRX) stake by 6.9% in Q2 2026, buying an estimated $55.8K and bringing the position to 16,585 shares worth $930K. The position accounts for 0.01% of the portfolio, ranked #1005.
Vident Advisory first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.
- Vident Advisory held 16,585 shares of Royalty Pharma worth $930K as of Q2 2026.
- Vident Advisory bought 1,073 Royalty Pharma shares in Q2 2026, an estimated $55.8K.
- Royalty Pharma made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1005 holding.
- Vident Advisory first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
- 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.
Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.